# Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

> **NCT07226154** · — · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Small RNA sequencing
- **DIAGNOSTIC_TEST:** PRECEPT assay (qRT-PCR validation)

## Key facts

- **NCT ID:** NCT07226154
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2026-06-18
- **Final completion:** 2026-06-18
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07226154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07226154, "Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07226154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*